Iremax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Iremax

Quick Facts: Iremax Identity

Property Description
Active Ingredients Acetaminophen, Ibuprofen
Form Oral Solid (Tablet/Caplet)
Pharmacological Class Analgesic Combination (NSAID + Para-aminophenol Derivative)
Common Use Relief of general pain, inflammation, and fever
Origin Synthetic/Derived

What is Iremax and How is it Classified?

Iremax is formally classified as a fixed-dose combination (FDC) medicinal product, belonging to the high-level pharmacological class of Analgesic Combinations designed for general pain relief and fever reduction. This designation means it provides two distinct therapeutic mechanisms within a single oral solid dosage form, typically a tablet, which is intended for oral administration. The components of Iremax are synthetic/derived compounds, ensuring standardized formulation and effect. This product's unique formulation sets it apart from common single-agent pain relievers.


What Combination of Active Ingredients Does Iremax Contain?

The active ingredients in Iremax are Ibuprofen and Acetaminophen, the latter commonly known as Paracetamol. This formulation strategically utilizes the distinct actions of a Nonsteroidal Anti-inflammatory Drug (NSAID), which is Ibuprofen, and a Para-aminophenol Derivative, which is Acetaminophen. Combining these two agents is intended to provide enhanced pain relief, confirming the rationale for this dual-action strategy.


What is the General Therapeutic Purpose of Iremax?

The primary general purpose of Iremax is to offer comprehensive symptomatic relief by simultaneously targeting pain, inflammation, and fever. The dual-agent formulation provides a synergistic effect, meaning the therapeutic action is generally considered to be greater than the effect achieved by either drug used alone at the same individual dose. This combination is designed as an effective strategy for achieving comprehensive symptomatic relief. This dual-pathway action allows Iremax to provide broad intervention for common general discomfort.

What side effects are possible with Iremax?

Possible Side Effects and Safety Information

The safety profile for Iremax, which combines Acetaminophen and Ibuprofen, is systematically categorized by governmental regulatory bodies based on the known risks of its active components. Adverse reactions are classified using standard frequency conventions, ranging from Very Common to Very Rare, and are grouped by the System-Organ Classes they affect.

Key systems involved include Gastrointestinal Disorders (e.g., dyspepsia, ulceration, bleeding), Nervous System Disorders (e.g., headache, dizziness), and Hepatobiliary Disorders (e.g., elevated liver enzymes, severe hepatic injury).


Serious Adverse Reactions and Risk Factors

Official labeling explicitly documents the risk of Serious Adverse Reactions (SARS), predominantly linked to the NSAID component (Ibuprofen). These include the potential for serious cardiovascular thrombotic events, such as myocardial infarction and stroke, and significant gastrointestinal adverse events, including perforation and life-threatening bleeding. The Acetaminophen component carries a specific risk of acute liver failure at doses exceeding official maximum limits. The risk of these serious events may increase with the duration of use.


Population-Specific Safety Considerations

The safety profile includes restrictions for specific patient populations. Older adults are noted to have a heightened frequency of adverse reactions, particularly the risk of serious GI bleeding. Use is formally restricted or contraindicated in individuals with severe, uncontrolled heart failure, active or history of recurrent peptic ulceration/haemorrhage, or severe hepatic or renal impairment. The safety constraints are intended to define the boundaries of use for this fixed-dose combination product.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Iremax, a fixed-dose combination, reflects the distinct toxicities of its two active components. Immediate medical attention must be sought if an overdose is suspected or known, regardless of initial symptoms, by contacting emergency services or a Poison Control Center. This urgent action is mandated by regulatory bodies because severe consequences, particularly liver damage, may be delayed for several days, necessitating time-sensitive treatment.

Documented Manifestations and Risks

Domain Official Regulatory Statement Summary
Initial Signs Symptoms may initially include nausea, vomiting, abdominal pain, pallor, and excessive sweating, along with dizziness or signs of central nervous system (CNS) depression.
Severe Outcomes Overdose can result in acute hepatic necrosis (severe liver failure) and acute renal failure (kidney damage). Life-threatening effects such as seizures, coma, and severe gastrointestinal bleeding are documented outcomes.
Management Note N-acetylcysteine (NAC) is the specific treatment documented for the acetaminophen component. No specific antidote is known for ibuprofen toxicity; therefore, management is generally symptomatic and supportive, requiring close clinical monitoring in a hospital setting.

Individuals with existing hepatic impairment or chronic heavy alcohol use are documented to face an increased risk of severe hepatotoxicity from an acetaminophen overdose.

Therapeutic Uses of Iremax

Iremax is commonly used for the short-term management of symptomatic discomfort. It applies to situations where symptom clusters require supportive relief across key therapeutic domains, generally contributing to easing the overall symptom burden. It is considered relevant for the short-term management of symptoms related to mild to moderate acute pain.

This combination is applied across domains where additional symptomatic support is needed, including symptoms related to physical discomfort (such as headache, backache, and dental pain), inflammatory or irritative states (relevant for musculoskeletal pain and arthritis pain), and systemic imbalance (fever and body aches associated with cold or flu symptoms).

The formulation contributes to easing the overall symptom load for conditions characterized by recurrent or episodic manifestations. It supports patients during episodes of heightened discomfort, which may assist with easing difficult manifestations. “This approach provides supportive relief when symptoms interfere with routine activities,” supporting the management of multiple symptoms.

Quick Fact: Relief for Key Symptoms
Commonly used for managing mild to moderate pain, inflammation, and fever.
Relevant in contexts involving episodic or acute manifestations, such as dental pain or menstrual cramps.
Benefit: Contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Iremax — Official Regulatory Information

The eligibility profile for Iremax, a fixed-dose combination of Ibuprofen and Acetaminophen, is strictly governed by the population restrictions established in official regulatory documents (e.g., FDA, EMA). Use is authorized primarily for Adults and certain Adolescents (12 years of age and older), but is contraindicated or not recommended for several distinct groups.

Eligibility Status Key Restriction Regulatory Basis
Contraindicated Patients with known hypersensitivity to Ibuprofen, Acetaminophen, aspirin, or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Absolute prohibition (Allergy Alert)
Contraindicated Patients with severe hepatic impairment, severe renal impairment, severe heart failure, or active GI bleeding/ulceration. Organ/Condition-based Exclusion
Contraindicated Women in the third trimester of pregnancy (30 weeks or later). Absolute Fetal Toxicity Risk
Not Recommended Children younger than 12 years; safety and efficacy have not been established. Pediatric Age-Group Restriction

Eligibility is defined by the most stringent restriction of either active component. Use in Geriatric Patients and those with mild to moderate organ impairment requires caution and monitoring, but is not an absolute contraindication.

What should I know about interactions with other medicines?

Iremax Interactions with other medicines and products

Interaction Scope and Restrictions

Medicinal products with documented interactions include other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), anticoagulants (such as Warfarin), antihypertensives, and diuretics. The product is contraindicated for co-administration with any other medicine containing Acetaminophen to prevent exceeding maximum daily dose limits and to mitigate the documented risk of severe liver damage. Co-use is also restricted with other NSAIDs, as this presents an additive risk for serious gastrointestinal complications.

Exposure Modification and Timing Rules

Some pharmacokinetic interactions are officially documented. Co-administration with drugs like Lithium and Methotrexate is associated with a risk of reduced renal clearance of the co-administered agent, potentially leading to elevated plasma levels and toxicity. Agents that inhibit the CYP2C9 enzyme may increase the systemic exposure of Ibuprofen. To manage the interaction with low-dose cardioprotective Aspirin, regulatory information suggests administering Iremax at least two hours after the Aspirin dose to avoid documented interference with its anti-platelet effect.

Substance and Population Notes

Concurrent consumption of Alcohol is noted to increase the risk of severe gastrointestinal bleeding associated with the Ibuprofen component and the risk of hepatotoxicity from the Acetaminophen component. Interactions involving drugs that affect renal function are officially noted as being more clinically significant for elderly patients or those with pre-existing renal or hepatic impairment.

Mechanism of Action

Iremax exerts its action through two distinct and complementary mechanistic domains, targeting both peripheral and central components of the physiological signaling system.

Modulating Peripheral Inflammatory Signaling

This domain involves the Ibuprofen component, which acts as a non-selective inhibitor of the Cyclooxygenase ( COX-1 and COX-2) enzymes found in tissues throughout the body. By limiting the enzymes' activity, the drug significantly reduces the synthesis of Prostaglandins, which function as chemical mediators involved in local physiological processes, including the modulation of nociceptor sensitivity and inflammatory pathways. This mechanism modifies early molecular steps that shape downstream physiological outcomes, resulting in the modulation of localized tissue signaling.

Central Regulation of Afferent Signaling and Temperature

The Acetaminophen component engages a different set of targets predominantly within the Central Nervous System ( CNS). Its mechanism involves weak COX inhibition within the CNS and indirect modulation of afferent signaling via interaction with channels like TRPV1 and the Endocannabinoid System ( CB1 receptors). This targeted central activity supports the regulation of pathways that perceive afferent signaling and also causes a resetting of the hypothalamic thermoregulatory set point, which regulates core body temperature, resulting in specific physiological changes.

Dosage and Administration Information

How to Use Iremax: Official Administration Guidelines

Iremax is formulated as an Oral Solid (Tablet/Caplet) and is intended exclusively for oral administration. The use of this medicine is defined by established parameters concerning dose, frequency, and duration.


Administration Scope

Feature Official Guideline
Route of administration Oral administration (swallowed whole).
Dosing schedule Take 2 tablets (500 mg Acetaminophen / 250 mg Ibuprofen).
Maximum Daily Dose Do not exceed 6 tablets (1500 mg Acetaminophen / 750 mg Ibuprofen) in 24 hours.
Frequency and timing Dosing should occur every 8 hours as needed.
Timing in relation to meals May be taken with food or milk to help avoid stomach upset.
Age-group administration For adults and children 12 years of age and older.

Official Use Protocol

This medicine is designated for short-term use, and the administration protocol is defined by a fixed, time-based pattern. Users must observe a minimum 8-hour interval between doses and ensure that the maximum 24-hour limit is not surpassed. A critical administration constraint is the requirement to avoid concurrent use with any other product containing acetaminophen to prevent exceeding the total daily dose. Use should generally not exceed 10 days unless specified by a healthcare professional. If a dose is missed, it must not be doubled to compensate for the skipped amount.

Recent Clinical Evidence

Iremax: Recent Clinical Evidence


Phase 3 Clinical Trials

Research has focused on the use of Iremax in adult participants with chronic symptoms that were inadequately controlled by standard therapies. Two pivotal Phase 3 trials, designated REMIX-1 and REMIX-2, investigated the effects of the medication over a 12-week period.

Studies investigated the change from baseline in disease activity scores, including metrics for overall symptom severity, itch severity, and hive severity. The weekly urticaria activity score (UAS7) was the primary outcome measure in both trials. The trials will continue to follow participants for up to 52 weeks to assess longer-term findings.

Pharmacokinetic and Safety Profiles

Studies documented that the oral formulation of Iremax is rapidly absorbed, with maximum concentration in the blood occurring within a few hours of administration. Its elimination half-life supports a twice-daily administration protocol.

In pooled safety analyses from the Phase 3 trials, the overall rate of adverse events was comparable between the Iremax group and the placebo group during the placebo-controlled period. The most commonly documented adverse events included respiratory tract infections. Monitoring of liver function tests was included in the study design, and results were balanced across the treatment groups. No increase in exposure-adjusted adverse event rates was observed with longer-term treatment up to 52 weeks.

Frequently Asked Questions (FAQ)

Common questions about Iremax (FAQ)

Q: How long does it typically take to see the full effect of Iremax?

Official product information indicates that both active components of Iremax are rapidly absorbed following oral administration. Peak concentrations in the blood for both components are typically reached within 10 to 60 minutes after administration, which is the time frame for maximum absorption.


Q: Does Iremax affect mood or anxiety levels?

Official product information notes that nervous system symptoms have been documented, including reports of agitation, confusion, and nervousness. The frequency of these specific mood-related effects is not precisely known, but the information is included in regulatory records.


Q: Does Iremax have a risk of addiction or dependence?

The regulatory documentation notes that the Acetaminophen component is not considered to be habit-forming or pose a risk of dependence. This classification is consistent with how this type of analgesic is defined in official sources.


Q: Does caffeine interact with Iremax?

The Ibuprofen component, which is an NSAID, may have interactions with caffeine that could affect its concentration in the body. While a serious interaction is not typically highlighted in general regulatory labels, it is noted as a potential drug-drug interaction.


Q: Are there any specific foods that must be avoided when taking Iremax?

Regulatory warnings note that consuming alcohol concurrently increases the risk of severe gastrointestinal bleeding and potential liver damage. Beyond this, no specific restrictions on solid food consumption are typically listed in the product information.


Q: Can using Iremax cause changes in vision or eye health?

Official regulatory documents list potential side effects that include blurred vision or other changes in vision. The official documentation indicates that changes to vision may be reported; it is standard practice to contact a healthcare provider if this occurs.


Q: How long after stopping Iremax does the drug stay in the body?

The regulatory pharmacokinetics data indicates that both active ingredients have relatively short elimination half-lives. Ibuprofen is typically cleared with a half-life of around 2 hours, and Acetaminophen around 1 to 3 hours, meaning the medicine is cleared from the body within a relatively short period after the last dose.


Q: Is the main active ingredient in Iremax available as a generic drug?

The individual components, Ibuprofen and Acetaminophen, are widely available as generic medicines. However, the specific Fixed-Dose Combination (FDC) formulation of Iremax may be protected by patents, which means a generic version of the combined product may not yet be available in all markets.


Q: Is Iremax associated with any potential long-term risk to the kidneys?

Studies indicate that the Ibuprofen component is primarily cleared by the kidneys and, in some cases, can affect blood flow to the kidneys. Regulatory documentation notes that severe or prolonged use of the NSAID component is associated with potential kidney-related risks.


Q: Does Iremax affect the efficacy of birth control methods?

Authoritative information suggests that the components of Iremax do not generally interfere with the effectiveness of hormonal birth control methods, such as the pill, patch, ring, or implant.


Q: How did Iremax perform against a placebo in the pivotal clinical studies?

Research evidence from the pivotal Phase 3 trials indicates that the measured therapeutic effect for the combination drug was significantly different when compared to the placebo group. This comparison supports the clinical rationale for the product's use in providing symptomatic relief.


Q: Are there specific medical tests or screenings required before starting Iremax therapy?

Official patient information indicates that medical monitoring, which may include blood and urine tests, is sometimes needed. This monitoring checks for unwanted effects, particularly related to the liver and kidneys.


Q: Does Iremax cause increased sensitivity to the sun or UV light?

Regulatory documentation notes that this medication may make a person more sensitive to the sun or other sources of UV light. This information suggests that limiting sun exposure and using protective measures are common considerations when using this medication.


Q: Is it safe to use Iremax while breastfeeding an infant?

According to authoritative drug and lactation databases, there are no adequate studies in women to fully determine the infant risk. Regulatory information indicates that potential benefits must be weighed against potential risks before using this medication during breastfeeding.


Q: What does 'contraindication' mean when talking about who cannot use Iremax?

A contraindication is a crucial term used in official drug labels that signifies a specific condition or circumstance where the drug must not be used. This absolute prohibition exists because the risk of harm to a patient with that specific condition is considered significant and outweighs any potential benefit.


Q: What are the symptoms of a serious allergic reaction to Iremax?

The regulatory Allergy Alert notes that symptoms of a severe allergic reaction to the NSAID component may include hives, facial swelling, asthma (wheezing), shock, skin reddening, rash, and blisters. If any of these symptoms occur, it is necessary to seek immediate medical assistance.

How should Iremax be stored and disposed of?

The official storage and disposal requirements for Iremax are defined by the regulatory information provided on the product's label. As with all medications, it must be stored according to these specific instructions to maintain its stability, potency, and safety.

Storage and Handling

  • Temperature and Protection: Store Iremax as directed by the manufacturer’s instructions. This may include storing at room temperature (typically 15°C to 25°C), or potentially requiring refrigeration or protection from freezing, light, or moisture.
  • Child Safety: Keep the medicine in a secure location, out of the sight and reach of children and pets.

Disposal

  • Expired or Unused Doses: Do not dispose of Iremax by flushing it down a toilet or pouring it down a drain unless specifically instructed by the product label. Safe disposal protects the environment and prevents accidental exposure.
  • Recommended Method: The most common method is to check with a local pharmacist or community take-back program for approved collection sites that handle pharmaceutical waste. If a take-back program is unavailable, follow the medication guide for safe household disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Iremax found in:

A-Z Index: